SpringWorks Net Income Per E B T from 2010 to 2024

SWTX Stock  USD 38.91  2.61  7.19%   
SpringWorks Therapeutics Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 0.78 in 2024. During the period from 2010 to 2024, SpringWorks Therapeutics Net Income Per E B T regression line of annual values had r-squared of  0.07 and arithmetic mean of  0.93. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
0.89
Current Value
0.78
Quarterly Volatility
0.04932236
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SpringWorks Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SpringWorks Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 923.7 K, Selling General Administrative of 207.4 M or Total Revenue of 5.2 M, as well as many indicators such as Price To Sales Ratio of 444, Dividend Yield of 0.0 or PTB Ratio of 3.86. SpringWorks financial statements analysis is a perfect complement when working with SpringWorks Therapeutics Valuation or Volatility modules.
  
Check out the analysis of SpringWorks Therapeutics Correlation against competitors.
For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Latest SpringWorks Therapeutics' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of SpringWorks Therapeutics over the last few years. It is SpringWorks Therapeutics' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SpringWorks Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Pretty Stable
   Net Income Per E B T   
       Timeline  

SpringWorks Net Income Per E B T Regression Statistics

Arithmetic Mean0.93
Geometric Mean0.93
Coefficient Of Variation5.28
Mean Deviation0.03
Median0.94
Standard Deviation0.05
Sample Variance0
Range0.216
R-Value(0.27)
Mean Square Error0
R-Squared0.07
Significance0.33
Slope(0)
Total Sum of Squares0.03

SpringWorks Net Income Per E B T History

2024 0.78
2023 0.89
2022 0.99
2021 1.0
2020 0.97

About SpringWorks Therapeutics Financial Statements

SpringWorks Therapeutics investors use historical fundamental indicators, such as SpringWorks Therapeutics' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SpringWorks Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 0.89  0.78 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.